When TDP-43 escapes from the nucleus, cells bungle mRNA processing, chopping up and splicing transcripts in the wrong places. Most studies have focused on retention of “cryptic” exons, but recent work ...
Inflammation is known to contribute to Alzheimer’s disease progression, fueling the buildup of tau and amyloid pathology, and yet epidemiology suggests that people with the chronic inflammatory ...
Phosphorylated tau isn’t just pathological junk; it helps the brain defend against viral infections. So claim scientists led by Rudolph Tanzi and William Eimer at Massachusetts General Hospital in ...
APOE4 was originally studied in the context of blood lipids and cardiovascular disease and first characterized at the protein level as one of three inherited ApoE isoforms with unique ...
Perlman Neurology Outpatient Clinic 8950 Villa La Jolla Drive Suite C129 La Jolla, CA92037 United States Visit Website Contact: Douglas Galasko, M.D Phone: 858-657-8540 E-mail: [email protected] ...
The center currently accepts only fresh brain donations from the general population, and does not bank Alzheimer's brains or brains with unspecified dementia. Normal controls are welcome, as are ...
Nicotinamide riboside (NR) is a patented analog of nicotinamide or Vitamin B3, and is sold as a dietary supplement under the brand name Tru Niagen. Cells use NR to synthesize NAD+, an essential ...
Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...
The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...
In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback